2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a ...

The company's worst days might be behind it.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...

A medical expert warned of the side effects of the newly launched weight loss drug Ozempic.

The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...

We recently published 13 Best ADR Stocks to Invest In. Novo Nordisk A/S (NYSE:NVO) is one of the best ADR stocks. Healthcare ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...